82.84
price down icon0.41%   -0.34
after-market After Hours: 82.84
loading
Merck Co Inc stock is traded at $82.84, with a volume of 8.69M. It is down -0.41% in the last 24 hours and up +1.68% over the past month. Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$83.18
Open:
$83.23
24h Volume:
8.69M
Relative Volume:
0.52
Market Cap:
$209.34B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
12.06
EPS:
6.87
Net Cash Flow:
$18.10B
1W Performance:
-0.42%
1M Performance:
+1.68%
6M Performance:
-18.50%
1Y Performance:
-35.03%
1-Day Range:
Value
$81.91
$83.58
1-Week Range:
Value
$81.91
$85.83
52-Week Range:
Value
$75.93
$134.63

Merck Co Inc Stock (MRK) Company Profile

Name
Name
Merck Co Inc
Name
Phone
908-740-4000
Name
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
Employee
75,000
Name
Twitter
@Merck
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
MRK's Discussions on Twitter

Compare MRK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
MRK
Merck Co Inc
82.84 209.34B 63.92B 17.43B 18.10B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
821.46 737.81B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.00 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
196.07 340.25B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.12 277.97B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
113.08 222.45B 53.22B 12.86B 14.85B 6.39

Merck Co Inc Stock (MRK) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Feb-18-25 Downgrade Deutsche Bank Buy → Hold
Feb-10-25 Downgrade TD Cowen Buy → Hold
Jan-08-25 Downgrade Truist Buy → Hold
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-10-24 Resumed BofA Securities Buy
Dec-04-24 Upgrade HSBC Securities Hold → Buy
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-11-24 Downgrade Daiwa Securities Buy → Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Mar-11-24 Downgrade Societe Generale Hold → Sell
Jan-04-24 Upgrade TD Cowen Market Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Buy
Oct-27-23 Upgrade BMO Capital Markets Market Perform → Outperform
Oct-20-23 Upgrade UBS Neutral → Buy
Jul-14-23 Initiated HSBC Securities Hold
Apr-13-23 Upgrade Citigroup Neutral → Buy
Mar-28-23 Downgrade Societe Generale Buy → Hold
Mar-13-23 Downgrade Wells Fargo Overweight → Equal Weight
Mar-06-23 Initiated Jefferies Buy
Feb-22-23 Upgrade Wolfe Research Peer Perform → Outperform
Jan-04-23 Upgrade BofA Securities Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
Oct-10-22 Upgrade Guggenheim Neutral → Buy
Sep-14-22 Upgrade Berenberg Hold → Buy
Jul-06-22 Upgrade Daiwa Securities Neutral → Buy
Jun-06-22 Resumed SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Dec-17-21 Initiated Goldman Buy
Dec-16-21 Initiated Daiwa Securities Neutral
Dec-13-21 Downgrade UBS Buy → Neutral
Dec-09-21 Initiated Wells Fargo Overweight
Dec-07-21 Downgrade Guggenheim Buy → Neutral
Nov-29-21 Downgrade Citigroup Buy → Neutral
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-01-21 Upgrade Argus Hold → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-27-21 Resumed Truist Buy
May-20-21 Downgrade Argus Buy → Hold
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Aug-03-20 Upgrade Goldman Neutral → Buy
Jun-12-20 Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Oct-17-19 Resumed BofA/Merrill Neutral
Aug-16-19 Initiated SVB Leerink Outperform
Jul-03-19 Initiated Mizuho Buy
May-28-19 Initiated Goldman Neutral
May-13-19 Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18 Reiterated Citigroup Buy
Oct-09-18 Resumed Guggenheim Buy
Apr-23-18 Upgrade Goldman Neutral → Buy
Apr-17-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18 Upgrade Barclays Equal Weight → Overweight
Mar-12-18 Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18 Reiterated Leerink Partners Mkt Perform
Feb-07-18 Reiterated Morgan Stanley Equal-Weight
Jan-16-18 Upgrade SunTrust Hold → Buy
View All

Merck Co Inc Stock (MRK) Latest News

pulisher
May 05, 2025

Long-Term Investors in shares of Merck & Co., Inc. (NYSE: MRK) - openPR.com

May 05, 2025
pulisher
May 05, 2025

Merck & Co Unusual Options Activity - Nasdaq

May 05, 2025
pulisher
May 05, 2025

Is Merck & Co., Inc. (MRK) The Most Profitable Cheap Stock to Buy Now? - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

FDA Action Alert: GSK, Sanofi, Merck and More - BioSpace

May 05, 2025
pulisher
May 04, 2025

Merck invests $1B in Wilmington facility to boost U.S. drug production amid tariff concerns - Audacy

May 04, 2025
pulisher
May 03, 2025

Merck Expands Biomanufacturing with Staggering Investment in Wilmington - VISTA.Today

May 03, 2025
pulisher
May 02, 2025

Merck & Co., Inc. SEC 10-Q Report - TradingView

May 02, 2025
pulisher
May 02, 2025

Merck Stock Price | MRK Stock Quote, News, and History - markets.businessinsider.com

May 02, 2025
pulisher
May 02, 2025

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology - insights.citeline.com

May 02, 2025
pulisher
May 02, 2025

Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® - GlobeNewswire Inc.

May 02, 2025
pulisher
May 01, 2025

Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company” - Insider Monkey

May 01, 2025
pulisher
May 01, 2025

Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive

May 01, 2025
pulisher
May 01, 2025

June 13th Options Now Available For Merck (MRK) - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

AmacaThera and Merck Animal Health Announce Collaboration in Animal Health - Newswire.ca

May 01, 2025
pulisher
Apr 30, 2025

Pharmaceutical company Merck to invest $1 billion in Delaware plant - The American Bazaar

Apr 30, 2025
pulisher
Apr 30, 2025

Is Merck & Co. Inc. (MRK) the Best Dow Stock for the Next 12 Months? - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

In Brief: Merck To Invest $1bn In New US Biologics Production - insights.citeline.com

Apr 30, 2025
pulisher
Apr 30, 2025

Merck & Co courts Washington with Delaware build statement - The Pharma Letter

Apr 30, 2025
pulisher
Apr 30, 2025

Merck Shareholder Drops Suit Against Execs Over Gardasil Demand - Bloomberg Law News

Apr 30, 2025
pulisher
Apr 30, 2025

Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential - Insider Monkey

Apr 30, 2025
pulisher
Apr 30, 2025

Guggenheim Adjusts Merck & Co.'s Price Target to $108 From $115 - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

Guggenheim cuts Merck stock target to $108, keeps Buy rating By Investing.com - Investing.com India

Apr 30, 2025
pulisher
Apr 30, 2025

Merck (MRK) Price Target Reduced by Guggenheim Analyst | MRK Sto - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Merck & Co. (MRK) Looks to New Cholesterol Drug as Keytruda Expiration Looms - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.

Apr 30, 2025
pulisher
Apr 29, 2025

Merck plans to move manufacturing of its biggest drug, Keytruda, to a new US factory and lab in Delaware - The Daily Gazette

Apr 29, 2025
pulisher
Apr 29, 2025

Merck breaks ground at Chestnut Run - WDEL.com

Apr 29, 2025
pulisher
Apr 29, 2025

How To Put $100 In Your Retirement Fund Each Month With Merck Stock - Benzinga

Apr 29, 2025
pulisher
Apr 29, 2025

Merck to invest $1 billion in new Delaware plant to boost US manufacturing - Reuters

Apr 29, 2025
pulisher
Apr 29, 2025

Merck plans to bring Keytruda production to the US with $1B biologics factory - Endpoints News

Apr 29, 2025
pulisher
Apr 29, 2025

Is Merck & Co., Inc. (MRK) the Worst-Performing Blue Chip Stock So Far in 2025? - Insider Monkey

Apr 29, 2025
pulisher
Apr 29, 2025

Merck to build $1B biologics center in Wilmington - The Business Journals

Apr 29, 2025
pulisher
Apr 29, 2025

Merck Begins Construction of $1 Billion Biologics Facility in Delaware - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Merck to invest $1 billion in U.S. drug manufacturing plant - CBS News

Apr 29, 2025
pulisher
Apr 29, 2025

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware | MRK Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Merck (MRK) to Invest $1 Billion in Delaware Manufacturing Plant - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Merck Breaks Ground On New $1 Billion Biologics Center Of Excellence In Wilmington, Delaware - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Merck (MRK) Commences Construction on Advanced Biologics Facilit - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Merck to build $1B Delaware plant to ensure domestic supply of Keytruda (MRK:NYSE) - Seeking Alpha

Apr 29, 2025
pulisher
Apr 29, 2025

Stock Watch: Sanofi, Merck Open Windows Into Geopolitical Risks - insights.citeline.com

Apr 29, 2025
pulisher
Apr 29, 2025

Merck to invest $1 billion in new US site - breakingthenews.net

Apr 29, 2025
pulisher
Apr 29, 2025

Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Merck To Spend $1 Billion On New Factory To Make U.S. Supplies Of Cancer Drug Keytruda- WSJ - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Exclusive | Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster DrugWSJ - WSJ

Apr 29, 2025
pulisher
Apr 28, 2025

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label - insights.citeline.com

Apr 28, 2025
pulisher
Apr 28, 2025

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large - insights.citeline.com

Apr 28, 2025
pulisher
Apr 28, 2025

Merck acquires SpringWorks Therapeutics in multibillion dollar deal - The American Bazaar

Apr 28, 2025
pulisher
Apr 28, 2025

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Jim Cramer Says Merck & Co (MRK) Has ‘Turned Into a Complete Nightmare’ - Insider Monkey

Apr 28, 2025

Merck Co Inc Stock (MRK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general NVS
$113.08
price down icon 1.06%
$280.06
price down icon 0.41%
drug_manufacturers_general NVO
$69.12
price down icon 0.16%
$102.81
price down icon 0.84%
drug_manufacturers_general PFE
$23.87
price down icon 1.36%
Cap:     |  Volume (24h):